SENIOR MANAGEMENT

• Wayne Phillips CEO
• Market research UK
  INTERNATIONAL MARKET RESEARCH
  • Fabrice Allum: Board Director
  • Matthew Brooks: Director, Strategic MR
  • Anna Garofalo: Director, Strategic MR
  • Bridget Pumfrey: Director, Strategic MR
  • Sean Davies: Director, Strategic MR
  • Charlotte Savege: Director
  • Barry Crook: Director
  • Amanda Siebols: Research Consultant
• Market Research US
  INTERNATIONAL & US DOMESTIC
  MARKET RESEARCH
  • Jim Goldenberg: President
  • Thomas Hartford (T.H.) Kern: Senior Vice President, Strategic MR
  • Sally Davis: Senior Vice President,
    Strategic MR
    
  • Margie Sherr: Senior Vice President,
    Strategic MR
    
  • Andrea Stoltz: VP, Project Management
  • Rebekkah Carney: MIM VP, Medtech Market Research
  • Carolyn Ivins: Vice President
• Market Access and Consulting UK
  • Mike Mallinson: Managing Director
  • Shrinivas Rao Mukku: Lead Consultant, Global P&R
  • Robert White: Consultant
  • Enrico de Nigris: Consultant
  • Graeme Roberts: Consultant
  • Anna Gannedahl: Consultant
  • Henry Dummett: Consultant [Emerging Markets]
  • Ben Shankland: Consultant [Emerging Markets]
• Market Access and Consulting US
  • Michael Rizzo: Vice President
  • Caryn A. Zieses: Senior Consultant

Robert White

MARKET ACCESS CONSULTANT

rwhite@dhelixc.co.uk
+44 (0)20 7299 9830

Rob brings over 20 years of pharmaceutical industry experience to the Consulting division. He has led on key Market Access initiatives within cardiovascular disease, diabetes, asthma, pain management, oncology and HIV. Most recently he led on Market Access, for the joint venture, between Merck and Schering Plough working on the mega brand Zetia (Ezetimibe) and also for Merck on its new DPP4-Inhibitor, Januvia (Sitagliptin).

Rob has also developed global payer strategies and helped local operating companies to develop country specific value propositions. Within the UK he has specialised on payer engagement at national, regional and local levels and has developed market access initiatives for many brands. Rob conducts a great deal of training for Key Account Management teams on addressing payers and issues within markets often brought about by restrictive formularies and guidelines.

Within DHC he has worked on key projects for global pharmaceutical companies in market access, P&R and within global Health Technology Assessment bodies.